<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03180281</url>
  </required_header>
  <id_info>
    <org_study_id>XJTU1AF2016LSL-048</org_study_id>
    <nct_id>NCT03180281</nct_id>
  </id_info>
  <brief_title>Therapies on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity Which Protect Islet β Cell</brief_title>
  <acronym>TOND</acronym>
  <official_title>Exploring Effective and Safety Therapies Which Protect Islet β Cell on Newly Diagnosed Type 2 Diabetes Patients With High Glucose Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>First Affiliated Hospital Xi'an Jiaotong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prevalence of diabetes is increasing rapidly both in China and all over the
      world.Hyperglycemia is an important risk factor and major hazard to cardiovascular and
      cerebrovascular diseases and even dangerous to human health.&quot;High glucose toxicity &quot;cause
      pancreatic β cell non-physiologic and irreversible damage.It is an important cause of β cell
      dysfunction.High glucose toxicity further suppresses insulin secretion of β cell, further
      even β-cell function failure.It is urgent to explore more effective and safety treatments
      which can also protect islet cells function.How to release high glucose toxicity , reverse
      the toxic effects of hyperglycemia on islet β cells as early as possible, and to maximize
      recover and protect the pancreatic β cell function is the keypoints of this study.Our aim is
      to explore the non-inferiority of new antidiabetic drugs DPP4 inhibitors on releasing glucose
      toxicity and protecting islet β cell function compared with traditional treatments on newly
      diagnosed type 2 diabetes,compare efficacy and safety of different oral antidiabetic drugs
      and insulin on newly diagnosed type 2 diabetes patients with high glucose toxicity and
      compare differences of different oral antidiabetic drugs and insulin on protecting pancreatic
      β-cell function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients were divided into 3 groups:

        1. DPP-4 inhibitor treatment group (45 cases): DPP-4 inhibitor (sitagliptin phosphate)
           combined with metformin and/or acarbose;

        2. insulin treatment group (45 cases): insulin (insulin glargine or insulin detemir) and/or
           metformin;

        3. Sulfonylureas treatment group (45 cases): sulfonylureas combined with metformin and/or
           acarbose;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2017</start_date>
  <completion_date type="Anticipated">January 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting blood glucose,glycosylated hemoglobin(GHbA1c)</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 3 months</time_frame>
    <description>mmol/L,%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight loss</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 3 months</time_frame>
    <description>kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid changes</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 3 months</time_frame>
    <description>mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypoglycemia</measure>
    <time_frame>From date of randomization until the date of first documented progression, assessed up to 3 months</time_frame>
    <description>times</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">135</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>DPP4 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DPP4 inhibitor,1 pill qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>insulin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>insulin,glargine or detemir，0.2U/Kg,qd</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SU group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SU,Glimepiride，1-2mg qd</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DPP4</intervention_name>
    <description>sitagliptin phosphate 100mg qd</description>
    <arm_group_label>DPP4 group</arm_group_label>
    <other_name>sitagliptin phosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>Insulin Glargine or detemir 0.2U/kg qd</description>
    <arm_group_label>insulin group</arm_group_label>
    <other_name>Glargine or detemir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SU</intervention_name>
    <description>Glimepiride 1-2mg qd</description>
    <arm_group_label>SU group</arm_group_label>
    <other_name>Glimepiride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  newly onset

          -  type 2 diabetes

          -  BMI 18-30kg/m2

          -  FBS≧11.1mmol/L，GHbA1c≧9%

          -  urine ket ≦(1+)

          -  Normal liver and kidney function

        Exclusion Criteria:

          -  type 1 diabetes

          -  renal or hepatic insufficiency

          -  Severe ketoacidosis

          -  Treatment with corticosteroids, immunosuppressive agents or cytotoxic drugs

          -  Severe systemic disease

          -  History of pancreatitis or pancreatic surgery

          -  Pregnant and lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Sui, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Affiliated Hospital of Xi'an Jiao Tong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Sui, Doctor</last_name>
    <phone>0086-18991989230</phone>
    <email>suijing1029@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiao Tong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Sui, Doctor</last_name>
      <phone>0086-18991989230</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>June 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 8, 2017</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Detemir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

